The aggravating fury rituximab obliterated

Haematologica. 2024 Jun 1;109(6):2016-2018. doi: 10.3324/haematol.2023.284309.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Female
  • Humans
  • Male
  • Rituximab* / therapeutic use

Substances

  • Rituximab
  • Antineoplastic Agents, Immunological